These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26665779)

  • 21. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
    Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P
    Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.
    Kallner HK; Christensson AA; Elmér C; Flam B; Altman D
    Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():167-72. PubMed ID: 27318184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Developments in the medical treatment of overactive bladder].
    Alcántara Montero A
    Semergen; 2016; 42(8):557-565. PubMed ID: 26671329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
    Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
    BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study.
    Švabík K; Mašata J; Krhut J; Zachoval R; Hanuš T; Halaška M; Martan A
    Ceska Gynekol; 2018; 83(3):164-168. PubMed ID: 30764614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
    Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
    Takahashi S; Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR).
    Griebling TL; Campbell NL; Mangel J; Staskin D; Herschorn S; Elsouda D; Schermer CR
    BMC Geriatr; 2020 Mar; 20(1):109. PubMed ID: 32183741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
    Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mirabegron: a review of its use in patients with overactive bladder syndrome.
    Sanford M
    Drugs; 2013 Jul; 73(11):1213-25. PubMed ID: 23818156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
    Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
    Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirabegron for overactive bladder syndrome.
    Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
    de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
    Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
    Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
    Angulo JC; Khullar V; Nitti VW; Siddiqui E
    Actas Urol Esp; 2013; 37(10):640-51. PubMed ID: 23850394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
    Tyagi P; Tyagi V
    IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.